乌司他丁联合醒脑静治疗急性脑出血的疗效及对患者血清hs-CRP, D-D, NSE水平的影响

目的:探讨急性脑出血(ACH)应用乌司他丁(UTI)联合醒脑静治疗的临床效果及对患者血清超敏C反应蛋白(hs-CRP)、D-二聚体(D-D)、神经元特异性烯醇化酶(NSE)水平的影响。方法:选取我院2015年1月~2016年12月收治的110例ACH患者,按照随机数字表法均分为两组。对照组仅予以UTI治疗,观察组予UTI联合醒脑静治疗。记录比较两组脑水肿吸收疗效,治疗前后NIHSS评分、血清hs-CRP、D-D及NSE水平,并评价两组用药安全性。结果:治疗14d后,观察组脑血肿吸收的总有效率为89.1%,显著高于对照组的67.3%(P0.01)。两组治疗14 d后NIHSS评分均显著低于治疗前(P0.01),观察组治疗14 d后NIHSS评分的改善效果较对照组更为显著(P0.01)。与治疗前对比,两组治疗14 d后血清hs-CRP、D-D及NSE水平均显著降低(P0.01),且观察组治疗14 d后血清学指标的改善效果均显著优于对照组同期(P0.01)。观察组不良反应率为3.6%,与对照组的5.5%相比差异无统计学意义(P0.05)。结论:乌司他丁联合醒脑静治疗更能迅速缓解或消除急性脑出血患者的血肿,控制机体炎性反应,改善凝血系统与纤溶系统状态,保护神经细胞,减轻神经功能损伤,效果显著且安全性高。

Ulinastatin Combined with Xingnaojing Injection in Treatment of Acute Cerebral Hemorrhage and Serum hs-CRP, D-D and NSE Levels

ABSTRACT Objective: To investigate ulinastatin (UTI) combined with Xingnaojing injection in the treatment of acute cerebral hemorrhage (ACH) and its effect on the serum high sensitivity C reactive protein (hs-CRP), D-dimer (D-D) and neuron specific enolase (NSE) levels. Methods: 110 cases of ACH patients admitted in our hospital from January 2015 to December 2016 were selected and divided into two groups according to the random number table method. The control group was given UTI treatment, while the observation group was given UTI combined with Xingnaojing treatment. Then the brain edema absorption effect, NIHSS score, serum hs-CRP, D-D and NSE levels before and after the treatment of the two groups were recorded and compared; the safety of medicidstion of the two groups was evaluated. Results: At the 14th day after treatment, the total effective rate of cerebral hematoma absorption in the observation group was 89.1%, which was significantly higher than 67.3% of the control group (P<0.01). At the 14th day after treatment, the NIHSS scores of both groups were significantly lower than those before the treatment (P<0.01); compared with that of the control group of the same time period, at the 14th day after treatment, the improvement effect of NIHSS score in the observation group was more significant (P<0.01). Compared with those before the treatment, the serum hs-CRP, D-D and NSE levels of both groups at the 14th day after treatment were significantly decreased (P<0.01); at the 14th day after treatment, the serum indicators of the observation group improved more significantly than those of the control group (P<0.01). The incidence rate of adverse reaction in the observation group was 3.6% compared with 5.5% of the control group(P>0.05). Conclusion: Ulinastatin combined with Xingnaojing Injection could rapidly relieve or eliminate hematoma in the treatment of acute cerebral hemorrhage, control the inflammatory response, improve the blood coagulation system and fibrinolytic system, protect the nerve cells and reduce the neurological damagee.